How Does CBG Administration Affect Sphingolipid Deposition in the Liver of Insulin-Resistant Rats?

Wiktor Bzdega Piotr Franciszek KurzynaEwa Harasim-SymborAdam HołowniaAdrian Chabowski Karolina Konstantynowicz-Nowicka

Published in: Nutrients (2023)

The results suggest that CBG treatment may modulate sphingolipid metabolism in the liver and plasma, potentially protecting the liver against the development of metabolic disorders such as insulin resistance.

Keyphrases

insulin resistance
type diabetes
metabolic syndrome
skeletal muscle
high fat diet
polycystic ovary syndrome
combination therapy